Skip to main content

BIOS Memory SPV I, LP's Form 4 filing

Cognition Therapeutics Inc (CGTX) · filed Oct 15, 2021

Accession no.
0001104659-21-126906
Filed
Oct 15, 2021, 9:54 PM ET
Trade date
Oct 13, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 18 non-derivative transactions and 14 derivative transactions. Open-market purchases total $2.28M. Open-market sales total $1.08K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
BIOS Memory SPV I, LPCIK 000164374910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 13, 2021Common StockCConversionAcquired+1,424,014–F1–1,424,014Direct
Oct 13, 2021Common StockCConversionAcquired+418,926–F1–418,926Indirect
Oct 13, 2021Common StockCConversionAcquired+245,029–F1–245,029Indirect
Oct 13, 2021Common StockCConversionAcquired+78,298–F2–78,298Indirect
Oct 13, 2021Common StockCConversionAcquired+255,765–F2–255,765Indirect
Oct 13, 2021Common StockCConversionAcquired+34,238–F2–34,238Indirect
Oct 13, 2021Common StockPPurchaseAcquired+23,341$12.00+$280,09257,579IndirectDuplicate filing
Oct 13, 2021Common StockCConversionAcquired+351,844–F2–351,844Indirect
Oct 13, 2021Common StockXIn-the-money exerciseAcquired+33,495$0.032+$1,071.84385,339IndirectDuplicate filing
Oct 13, 2021Common StockSSaleDisposed−90.28$12.00−$1,083.36385,248IndirectDuplicate filing
Oct 13, 2021Common StockCConversionAcquired+41,620–F2–41,620Indirect
Oct 13, 2021Common StockCConversionAcquired+24,263–F5–65,883Indirect
Oct 13, 2021Common StockPPurchaseAcquired+22,129$12.00+$265,54888,012IndirectDuplicate filing
Oct 13, 2021Common StockCConversionAcquired+596,899–F2–596,899Indirect
Oct 13, 2021Common StockCConversionAcquired+158,476–F5–755,375Indirect
Oct 13, 2021Common StockPPurchaseAcquired+144,530$12.00+$1,734,360899,905IndirectDuplicate filing
Oct 13, 2021Common StockCConversionAcquired+34,472–F2–34,472Indirect
Oct 13, 2021Common StockCConversionAcquired+25,593–F5–60,065Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 13, 2021Common StockCConversionDisposed−1,424,014$0.00$00Direct
Oct 13, 2021Common StockCConversionDisposed−418,926$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockCConversionDisposed−245,029$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockCConversionDisposed−78,298$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockCConversionDisposed−255,765$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockCConversionDisposed−351,844$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockCConversionDisposed−34,238$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockCConversionDisposed−41,620$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockCConversionDisposed−596,899$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockCConversionDisposed−34,472$0.00$00IndirectDuplicate filing
Oct 13, 2021Common StockXIn-the-money exerciseDisposed−33,495$0.00$00IndirectDuplicate filing
Oct 13, 2021Simple Agreement for Future EquityCConversionDisposed−24,263$0.00$00IndirectDuplicate filing
Oct 13, 2021Simple Agreement for Future EquityCConversionDisposed−158,476$0.00$00IndirectDuplicate filing
Oct 13, 2021Simple Agreement for Future EquityCConversionDisposed−25,593$0.00$00IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.

Referenced by the price of 3 transactions in Table I.

F2

The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.

Referenced by the price of 7 transactions in Table I.

F5

The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)